Gracell Biotechnologies to Report Second Quarter 2023 Financials on Monday, August 14, 2023
31 Julho 2023 - 5:02PM
Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global
clinical-stage biopharmaceutical company dedicated to developing
innovative and highly efficacious cell therapies for the treatment
of cancer and autoimmune diseases, today announced that it plans to
release unaudited financial results for the second quarter ended
June 30, 2023 and provide an update on recent developments prior to
the open of the U.S. financial markets on Monday, August 14, 2023.
The management team will host a live audio webcast and conference
call at 8:00 AM Eastern Time.
Conference call and webcast
details:Monday, August 14, 2023 @ 8:00am ETInvestor
domestic dial-in: (800) 715-9871 Investor international dial-in:
(646) 307-1963Conference ID: 2527305Live webcast
link: https://ir.gracellbio.com/news-events/events-and-presentations
A replay of the webcast will be available
on ir.gracellbio.com shortly after the conclusion of the
event for 90 days.
About GracellGracell Biotechnologies
Inc. ("Gracell") is a global clinical-stage biopharmaceutical
company dedicated to discovering and developing breakthrough cell
therapies. Leveraging its pioneering FasTCAR and TruUCAR technology
platforms and SMART CART™ technology module, Gracell is
developing a rich clinical-stage pipeline of multiple autologous
and allogeneic product candidates with the potential to overcome
major industry challenges that persist with conventional CAR-T
therapies, including lengthy manufacturing time, suboptimal cell
quality, high therapy cost and lack of effective CAR-T therapies
for solid tumors. For more information on Gracell, please
visit http://www.gracellbio.com/.
Follow @GracellBio on LinkedIn.
Media contacts
Marvin Tang
marvin.tang@gracellbio.com
Jessica Laub
jessica.laub@westwicke.com
Investor contacts
Gracie Tong
gracie.tong@gracellbio.com
Stephanie Carrington
stephanie.carrington@westwicke.com
Gracell Biotechnologies (NASDAQ:GRCL)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Gracell Biotechnologies (NASDAQ:GRCL)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024